{"disease":{"id":"flt3-tkd-mutation","name":"flt3 tkd mutation"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05193448","title":"A Non-interventional Ambispective Real-world Cohort of rEfractory and reLapsed (R/R) FLT3 Mutated Acute MyEloid Leukemia (AML) Patients Treated With Gilteritinib in FrANCE","phase":"","overall_status":"COMPLETED","enrollment_count":177,"lead_sponsor_name":"French Innovative Leukemia Organisation","has_results":false},{"nct_id":"NCT03620318","title":"Individual Patient Compassionate Use of Crenolanib","phase":"","overall_status":"AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Arog Pharmaceuticals, Inc.","has_results":false}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}